Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancersFlorence Coussy(Institut Curie), Ivan Bièche(Délégation Paris 5)Journal of Hematology & OncologyFebruary 22, 202010.1186/s13045-020-0846-yCited by 54SaveCiteExport RISWatch citationsRelated PapersClinical value of R-spondins in triple-negative and metaplastic breast cancers|British Journal of Cancer|2017|39<i>MED12</i> mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways|Oncotarget|2016|34